Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids

Behavioural Pharmacology

Volumn 16, Issue 5-6, 2005, Pages 487-496

  Ilan, Aaron B ^a,d   Gevins, A ^a   Coleman, M ^b   ElSohly, M A ^c   De Wit, H ^b  

^a SAM Technology   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d SFBRI   (United States)

Author keywords

Biomarker; Cannabis; CBC; CBD; Cognition; EEG; ERP; Human brain function; Neurophysiology; THC

Indexed keywords

CANNABICHROMENE; CANNABIDIOL; CANNABIS; DRONABINOL; PLACEBO;

ADULT; ARTICLE; ATTENTION; CIGARETTE SMOKING; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NEUROPHYSIOLOGY; NORMAL HUMAN; PSYCHOMETRY; TASK PERFORMANCE; WORKING MEMORY;

EID: 26044436588     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200509000-00023     Document Type: Article

References (54)

1. American Psychological Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: APA.
2. Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM (1992). Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther 261:114-122.
3. Bauer LO (2001). Electroencephalographic studies of substance use and abuse. In: Kaufman MJ (editor): Brain Imaging in Substance Abuse: Research, Clinical, and Forensic Applications. Totowa, New Jersey: Humana Press; pp. 77-112.
4. Berman JS, Symonds C, Birch R (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112:299-306.
5. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ (2004). An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425-433.
6. Carlini EA, Cunha JM (1981). Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol 21:417S-427S.
7. Chait LD, Pierri J (1992.) Effects of smoked marijuana on human performance: A critical review. In: Murphy L, Bartke A (editors): Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, Florida: CRC Press; pp. 387-423.
8. Consroe P, Snider SR (1986). Therapeutic potential of cannabinoids in neurological disorders. In: Mechoulam R (editor): Cannabinoids as Therapeutic Agents. Boca Raton, Florida: CRC Press; pp. 21-49.
9. Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. (2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology 29:417-426.
10. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185.
11. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RB (1976). Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin Pharmacol Ther 19:300-309.
12. Davis WM, Hatoum NS (1983). Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol 14: 247-252.
13. Derogatis L (1983). SCL-90-R Manual II. Towson, Maryland: Clinical Psychometric Research.
14. ElSohly HN, Turner CE, Clark AM, ElSohly MA (1982). Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J Pharm Sci 71:1319-1323.
15. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd (2000). Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 45:24-30.
16. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G (2004). Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology 47:1170-1179.
17. Folstein MF, Luria R (1973). Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3:479-486.
18. Frisk V, Milner B (1990). The relationship of working memory to the immediate recall of stories following unilateral temporal or frontal lobectomy. Neuropsychologia 28:121-135.
19. Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of active constituent of hashish. J Am Chem Soc 86:1646-1647.
20. Gevins A, Smith ME (2000). Neurophysiological measures of working memory and individual differences in cognitive ability and cognitive style. Cereb Cortex 10:829-839.
21. Gevins A, Smith ME, McEvoy L, Yu D (1997). High-resolution EEG mapping of cortical activation related to working memory: effects of task difficulty, type of processing, and practice. Cereb Cortex 7:374-385.
22. Gevins A, Smith ME, Leong H, McEvoy L, Whitfield S, Du R, et al. (1998). Monitoring working memory load during computer-based tasks with EEG pattern recognition methods. Hum Factors 40:79-91.
23. Gevins A, Smith ME, McEvoy LK (2002). Tracking the cognitive pharmacodynamics of psychoactive substances with combinations of behavioral and neurophysiological measures. Neuropsychopharmacology 26:27-39.
24. Hollister LE (1973). Cannabidiol and cannabinol in man. Experientia 29: 825-826.
25. Hollister LE, Gillespie HK (1973). Delta-8- and delta-9- tetrahydrocannabinol comparison in man by oral and intravenous administration. Clin Pharmacol Ther 14:353-357.
26. Hollister LE, Gillespie H (1975). Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol. Clin Pharmacol Ther 18:80-83.
27. Ilan AB, Gevins A (2001). Prolonged neurophysiological effects of cumulative wine drinking. Alcohol 25:137-152.
28. Ilan AB, Smith ME, Gevins A (2004). Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl) 176:214-222.
29. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28:172-177.
30. Karniol IG, Shirakawa I, Takahashi RN, Knobel E, Musty RE (1975). Effects of delta9-tetrahydrocannabinol and cannabinol in man. Pharmacology 13:502-512.
31. Kirk JM, Doty P, de Wit H (1998). Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 59:287-293.
32. Kutas M, Hillyard SA (1980). Reading senseless sentences: brain potentials reflect semantic incongruity. Science 207:203-205.
33. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ (2005). Acute marijuana effects on human risk taking. Neuropsychopharmacology 30: 800-809.
34. Levander S, Binder M, Agurell S, Bader-Bartfai A, Gustafsson K, Lindgren J, et al. (1974). Proceedings: Pharmacokinetics in relation to physiological and psychological effects of delta-8-THC. Acta Pharm Suec 11:662-663.
35. McEvoy LK, Smith ME, Gevins A (2000). Test-retest reliability of cognitive EEG. Clin Neurophysiol 111:457-463.
36. Mecklinger A, Opitz B, Friederici AD (1997). Semantic aspects of novelty detection in humans. Neurosci Lett 235:65-68.
37. Moreira FA, Guimaraes FS (2005). Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512:199-205.
38. Nicoll RA, Alger BE (2004). The brain's own marijuana. Sci Am 291:68-75.
39. Nordqvist M, Lindgren JE, Agurell S (1976). A method for the identification of acid metabolites of tetrahydrocannabinol (THC) by mass fragmentography. Cannabinoid Assays in Humans/USA: National Institute on Drug Abuse. NIDA Res Monogr 7:64-69.
40. Owen AM, Evans AC, Petrides M (1996). Evidence for a two-stage model of spatial working memory processing within the lateral frontal cortex: A positron emission tomography study. Cereb Cortex 6:31-38.
41. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R (2004). Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175:360-366.
42. Perez-Reyes M, Timmons MC, Davis KH, Wall EM (1973). A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia 29: 1368-1369.
43. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE (1982). Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 31:617-624.
44. Petrides M, Milner B (1982). Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia 20:249-262.
45. Selzer ML (1971). The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry 127:1653-1658.
46. Snodgrass JG, Corwin J (1988). Pragmatics of measuring recognition memory: Applications to dementia and amnesia. J Exp Psychol 117:34-49.
47. Struve FA, Straumanis JJ, Patrick G, Price L (1989). Topographic mapping of quantitative EEG variables in chronic heavy marihuana users: empirical findings with psychiatric patients. Clin Electroencephalogr 20:6-23.
48. Torsvall L, Åkerstedt T (1988). Extreme sleepiness: quantification of EOG and spectral EEG parameters. Int J Neursci 38:435-441.
49. Turner CE, ElSohly MA (1981). Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 21:283S-291S.
50. Turner CJ, Willis RJ (1980). The relationship of college students' use of marijuana to parental attitudes and drug-taking behavior. Int J Addict 15:1103-1112.
51. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. (2004). Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417-424.
52. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002). Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 161:331-339.
53. Wade DT, Makela P, Robson P, House H, Bateman C (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434-441.
54. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982). Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76:245-250.